Poster Viewing Sessions

More information will follow.

Four poster viewing sessions are organized during the 32nd Annual Meeting.7

More information about the schedule will follow soon.

Thursday, 21 November 2024

12:30 - 13:30Poster Viewing Session I
17:15 - 18:15Poster viewing II

Friday, 22 November 2024

10:00 - 10:30Poster Viewing Session III
13:00 - 14:00Poster viewing IV

During those sessions, our Young Investigators, ECF Fellows and Investigators will present their posters to the jury onsite. E-posters will be also available for consultation on the ECF website.

The winners of the 3 Young Investigators Awards (one Award per category) will be announced on Friday, 10 November 2023 from 17:20 - 17:30.

The winners will also present their posters during the Young Investigators Awards presentations which will be held on Saturday, 11 November 2023 from 10:30 - 11:00.

Title Location
12:30 - 13:30
Poster Viewing Session I - Clinical + Epidemiology
-- ID 2: MACSiMiSE-BRAIN: a multi-centre randomised placebo controlled clinical trial
Anna-Victoria De Keersmaecker
-- ID 11: Assessing the risk of relapse after in vitro fertilization in women with MS
Marie Mainguy
-- ID 21: Social Outcomes as a Measure of Recovery in Patients with Early Onset MS
Julian Lui
-- ID 23: Teriflunomide adherence in multiple sclerosis
Vincent van Pesch
-- ID 30: Cognitive Correlates of Apathy in Multiple Sclerosis: an 8-year longitudinal study
Mariachiara Gaita
-- ID 31: Premature thymic involution in MS and other autoimmune diseases
Wein-Na Jin
-- ID 33: Does MSWS-12, patient-reported outcome of walking ability, mirror ataxic symptoms?
Lina Anderhalten
Sofia Ntymenou
Sofia Ntymenou
-- ID 37: Cancer risk in MS: a 10-year nationwide study
Chloé Pierret
-- ID 38: PRIMUS: Reusing research data as decision support for precision medicine in MS
Stanislas Demuth
-- ID 44: Phase 3 REMODEL I/II Trials: Efficacy, Safety & Tolerability of Remibrutinib in RMS
Prof. Xavier Montalban
-- ID 47: Remibrutinib’s Safety Across Immune-Mediated Diseases Supports Development in MS
Prof. Xavier Montalban
-- ID 54: TRACK-MS: A new test to detect cognitive impairment in different subtypes of MS
Ms Daniela Taranu
-- ID 60: Epidemiological Trends and Disease Burden of Multiple Sclerosis from 1990 to 2019
Sara Samadzadeh​
-- ID 61: MOGAD Patient Spectrum: Insights from a Turkish Single-Center Study
Abdulkadir Tunç
-- ID 62: Fenebrutinib in multiple sclerosis–results from the phase II FENopta study
Prof. Dr Amit Bar-Or
-- ID 65: Validation of protein-MS associations by Mendelian randomisation in a large cohort
Shannon Bernard Healey
-- ID 67: Late Onset Multiple Sclerosis, Clinical Characteristics of a Mexican Group
Diana Gomez
-- ID 69: Decoding cognitive dysfunction in multiple sclerosis: role of brainstem atrophy
Eline Van Doninck
-- ID 71: Progressive multiple sclerosis: identifying distinct cognitive-affective profiles
Angela Boschetti
17:15 - 18:15
Poster Viewing Session II - Treatment + Investigations Part 1
-- ID 10: Circadian rhythm and interferon safety in multiple sclerosis
Dr Mehdi Maghbooli
-- ID 15: Safety and Efficacy of Tolebrutinib in RMS Participants: 3-Year Results
Dr Jiwon Oh
-- ID 16: MRI Outcomes from the LTS Study of Tolebrutinib in RMS Participants: 3-Year Results
Dr Jiwon Oh
-- ID17: Real-life outcome of teriflunomide treatment and its predictors in RRMS patients
Hongmei Tan
Louise Moelgaard
-- ID 26: Health-related effects in multiple sclerosis during functional training
Charlotte Klump
-- ID 27: Phase 3 trials of evobrutinib in relapsing MS: Design and baseline characteristics
Prof. Xavier Montalban
-- ID28: Long term (5-year) efficacy and safety of evobrutinib in patients with relapsing MS
Prof. Xavier Montalban
-- ID34: Effect of Evobrutinib on Vitality, Mental Health, and Fatigue in relapsing MS
Prof. Patrick Vermersch
-- ID 40: Patient preference and real-world outcomes of diroximel fumarate therapy in RRMS
Angela Guerra
-- ID 41: SISTER – Subcutaneous: Observational study on TYSABRI® Patient Preference
Angela Guerra
-- ID 42: Remibrutinib Ameliorates CNS Autoimmune Disease - Insights From EAE
Virginia DeLasHeras
-- ID 43: Remibrutinib Inhibits Neuroinflammation Driven by B cells and Myeloid Cells in EAE
Virginia DeLasHeras
Title Location
10:00 - 10:30
Poster Viewing Session III - Basic Studies
-- ID 5: The immunometabolic landscape of bone marrow cells in multiple sclerosis
Caiyun Qi
-- ID 6: The influence of dopamine on the monocyte-induced Th17-immune response in MS
Dr Mikhail Melnikov
-- ID 7: IRAK-M suppresses microglial NLRP3 inflammasome activation and pyroptosis in EAE
Bingtian Xu
-- ID 8: Reduced Aβ amyloid deposits relate to inflammation & neuronal survival in MS cortex
Dr Jonathan Pansieri
-- ID 9: Myelopoiesis and its therapeutic implication in multiple sclerosis
Kaibin Shi
-- ID 12: Physiological & inflammation induced aging impairs human oligodendroglial function
Ms Farina Windener
-- ID 13: APOE Bearing Astrocytic Extracellular Vesicles Alleviates NMOSD
Xindi Li
-- ID 14: Connexin hemichannel blockade ameliorates EAE by suppressing glial inflammation
Ezgi Ozdemir Takase
-- ID 24: CSF CHIT1 predicts disability progression and reflects microglia activation in MS
Stijn Swinnen
-- ID 45: Halting Brain Inflammation and Degeneration by Antagonizing FPR1
Prof. Fu-Dong Shi
-- ID 51: Immunoglobulin Deposition in the Progressive Multiple Sclerosis Spinal Cord
Andrew Lockhart
-- ID 53: Aberrant iron deposition in the MS spinal cord relates to neurodegeneration
Dr Marco Pisa
-- ID 58: Anodal tDCS promotes remyelination in the cuprizone model
Ms Elena Rossi
-- ID 59: Candidate MS progression associated genes in human stem cell-derived neural models
Mollie McKeon
-- ID 73: Transcorneal Electrical Stimulation modulates visual function in vivo
Dr Valerio Castoldi
13:00 - 14:00
Poster Viewing Session IV - Treatment + Investigations Part 2
-- ID 46: An evidence based Global MS Patient Charter created by a multi-stakeholder alliance
Pauline Gieseler
-- ID 48: Retrospective data analysis of a German cladribine cohort from MS treatment centres
Michael Ernst
-- ID 50: Evoked potentials to predict rehabilitation outcome in progressive MS
Alessandro Gradassi
-- ID 56: Extended interval dosing with ocrelizumab in multiple sclerosis
Dr Frederik Novak Stenstad
-- ID 57: Treatment switch from OFA to OCR in RMS: Two case reports
Tanja Maler
-- ID 63: Myelin PET imaging of cervical spinal cord is associated with disability in MS
Milena Pitombeira
-- ID 64: Lymphopenia in DMF: Are there characteristics that can predict its occurrence?
Diana Gomez
-- ID66: Vulnerability of thalamic nuclei at CSF interface during the entire course of MS
Dr Ismail Koubiyr
-- ID 68: Reference FLAIR lesion volumes for the follow up of MS patients
Annemie Ribbens
-- ID 70: EEG markers of cognitive involvement in MS: Event-Related Potentials to the SDMT
Marta Tacchini
-- ID 72: Remote digital Symbol-Digit Modalities Test in pwMS: Validity and Reliability
Mr Michelangelo Dini
13:00 - 14:00
Poster Viewing Session I - Clinical + Epidemiology
-- ID 52: Longitudinal MRI structural and cognitive measures in MOGAD and MS
Dr Valentina Camera
17:20 - 17:30
Announcement Young Investigator Award Winners
Title Location
10:30 - 11:00
Young Investigator Awards